Pfnex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the use of Pfnex Expression Technology"
San Diego, California, and Ingelheim,
Germany,
15 February 2011 – Pfēnex Inc., an
industry leader in protein expression through the Pfēnex
Expression Technology™ platform and Boehringer Ingelheim
International GmbH, a leading pharmaceutical company and global
leader in biopharmaceutical contract development and manufacture,
announced today that they have entered into a strategic agreement.
It provides Boehringer Ingelheim with non-exclusive access to the
Pfēnex Expression Technology. Under the terms of the
multi-year agreement, Pfenex Inc. will engineer production strains
and processes for Boehringer Ingelheim’s proprietary
molecules, and molecules from Boehringer Ingelheim’s contract
manufacturing customers. This collaboration provides Boehringer
Ingelheim and their customers with access to an industry-leading
expression platform to enable preclinical and clinical development
to progress much more quickly and efficiently.
“We are very pleased to have established this agreement with Boehringer Ingelheim,” said Dr Bertrand Liang, CEO of Pfenex Inc. “This partnership combines a cutting edge expression technology with the leading innovative pharmaceutical company and contract services provider, facilitating the speed and reliability with which important new drugs can be brought to patients.”
“This collaboration extends our contract manufacturing service portfolio by an additional high expression system and is a further step in our strategy to offer customers leading technologies”, stated Simon Sturge, Corporate Senior Vice President of the Biopharmaceuticals Division at Boehringer Ingelheim. “The Pfēnex Expression Technology™ delivers excellent expression rates, and we are looking forward to realizing customer projects with this technology."
